Background: The use of inflammatory biomarkers to delineate the type of lung inflammation present in asthmatic subjects is increasingly common. However, the effect of obesity on these markers is unknown. Objectives: We aimed to determine the effect of obesity on conventional markers of inflammation in asthmatic subjects. Methods: We performed secondary analysis of data from 652 subjects previously enrolled in 2 Asthma Clinical Research Network trials. We performed linear correlations between biomarkers and logistic regression analysis to determine the predictive value of IgE levels, blood eosinophil counts, and fraction of exhaled nitric oxide values in relationship to sputum eosinophil counts (>2%), as well as to determine whether cut points existed that would maximize the sensitivity and specificity for predicting sputum eosinophilia in the 3 weight groups.
Results: Overall, statistically significant but relatively weak correlations were observed among all 4 markers of inflammation. Within obese subjects, the only significant correlation found was between IgE levels and blood eosinophil counts (r 5 0.33, P < .001); furthermore, all other correlations between inflammatory markers were approximately 0, including correlations with sputum eosinophil counts. In addition, the predictive value of each biomarker alone or in combination was poor in obese subjects. In fact, in obese subjects none of the biomarkers of inflammation significantly predicted the presence of high sputum eosinophil counts. Obese asthmatic subjects have lower cut points for IgE levels (268 IU), fraction of exhaled nitric oxide values (14.5 ppb), and blood eosinophil counts (96 cells/mL) than all other groups. Conclusions: In obese asthmatic subjects conventional biomarkers of inflammation are poorly predictive of eosinophilic airway inflammation. As such, biomarkers currently used to delineate eosinophilic inflammation in asthmatic subjects should be approached with caution in these subjects. (J Allergy Clin Immunol 2018;141:1096-104.)
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An association exists between the development of asthma and increased body mass index (BMI). 1 Obesity in asthmatic patients is associated with increased symptoms, increased disease severity, and a decreased response to conventional medications. 2, 3 Additionally, it has been appreciated that obese subjects with asthma demonstrate phenotypic heterogeneity similar to that seen in lean subjects. 4 The most commonly accepted and welldescribed phenotype of asthma is one encompassed by eosinophilic inflammation resulting from type 2 cells that include CD4 and innate lymphoid cells that produce the cytokines IL-4, IL-5, and IL-13, among others. 5, 6 Eosinophilic inflammation is also associated with the presence of atopy and increased fraction of exhaled nitric oxide (FENO) values, serum IgE levels, sputum eosinophil counts, and peripheral blood eosinophil counts. 5, 7 Obesity is known to affect immune responses and alter T-cell function and eosinophil migration and might affect type II responses in a subgroup of obese asthmatic subjects. [8] [9] [10] Inflammatory biomarkers, such as sputum eosinophil counts, blood eosinophil counts, periostin levels, IgE levels, and FENO values, are increasingly being used to identify eosinophilic asthma phenotypes and predict response to therapy. [11] [12] [13] [14] [15] [16] The gold standard of eosinophilic inflammation is the identification of eosinophils in airway tissue through bronchoscopy and analysis of endobronchial biopsy specimens. However, this test is invasive and costly, limiting its use as a phenotyping tool. Sputum eosinophil counts have been used extensively in clinical trials as a marker of tissue eosinophilia, but induced sputum is generally unavailable for use as a clinical tool. In clinical trials sputum eosinophil measures have rapidly gained favor as being predictive of important asthma outcomes, although the correlation between sputum and tissue eosinophil counts is not always consistent with the proportion of subjects who demonstrate discordance between sputum and tissue eosinophilia. 17, 18 In this study we considered sputum eosinophils to be the gold standard of eosinophilic inflammation.
The limited availability of sputum eosinophil measurements in clinical settings has led to increased interest in surrogate markers of inflammation; however, these markers are not always accurately predictive of the presence of eosinophilic or neutrophilic inflammation. 19 In addition, the effect of obesity on the ability of biomarkers to accurately depict underlying eosinophilic inflammation is unknown. For instance, studies have shown that sputum eosinophil counts and FENO values predict the response to inhaled corticosteroids (ICSs), 14, 15, 20, 21 and treatment strategies aimed at reducing sputum eosinophils result in a reduction in asthma exacerbation rates. 22, 23 However, 2 recent publications report discordance between submucosal eosinophilia and both bronchoalveolar lavage and sputum eosinophilia in obese asthmatic subjects. 24, 25 FENO, a biomarker shown to correlate with eosinophilic inflammation, 18 is low in obese asthmatic subjects and therefore might not be predictive, 26, 27 but data are conflicting. 28 Blood eosinophil counts have become gradually accepted as a useful biomarker of asthma severity and are significantly decreased in response to anti-IgE and anti-IL-5 therapies. 11, 29, 30 Data supporting the use of blood eosinophil counts to predict response to ICSs are mixed, and widespread use of blood eosinophil counts as a biomarker has yet to occur. 31, 32 IgE has been a target of asthma therapy, but it appears that clinical characteristics, including a history of exacerbation, need for high-dose ICSs, and presence of low lung function, are better predictors of response to omalizumab than serum IgE levels. [33] [34] [35] However, a recent report suggested that peripheral eosinophil counts of greater than 260 cells/mL and FENO values of greater than 19.5 ppb, as well as serum periostin values of greater than 50 mg/mL (a biomarker associated with IL-13), were associated with the response to xolair. 36 Given the possible discordance between peripheral biomarkers and pulmonary inflammation in obese asthmatic subjects, we hypothesized that the presence of obesity in asthmatic subjects J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 would decrease the ability of FENO values, serum IgE levels, and peripheral blood eosinophil counts to predict sputum eosinophilia, which could subsequently decrease the ability to predict treatment responses.
METHODS

Study design
The Duke University Institutional Review Board approved this study (protocol no. Pro00056566), and data were obtained from the National Heart, Lung, and Blood Institute's Biologic Specimen and Data Repository Information Coordinating Center. Secondary analyses of data from a common run-in period in 2 Asthma Clinical Research Network trials were performed (n 5 652), including (1) Best Adjustment Strategy for Asthma over Long Term (BASALT; ClinicalTrials.gov no. NCT00495157, n 5 363) 37 and (2) Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC; ClinicalTrials.gov no. NCT00565266, n 5 289). 38 The inclusion criteria included age of 18 years or greater, a physician's diagnosis of asthma confirmed by a positive methacholine test result or the presence of FEV 1 reversibility by 12% and 200 mL after 4 puffs of inhaled albuterol, a baseline FEV 1 of more than 40% of predicted value, and a smoking history of less than 10 pack years. Exclusion criteria included the presence of other lung disease or respiratory tract infection or a significant asthma exacerbation within 4 weeks of study entry. During the run-in period, lung function testing, including spirometry, prebronchodilator and postbronchodilator FEV 1 measurement, and methacholine testing, was performed. FENO values were measured, and sputum induction was completed for differential cell counts. Additionally, all subjects had a serum IgE and peripheral eosinophil count measurements and skin prick tests performed. Subjects completed the Asthma Control Questionnaire, Asthma Quality of Life Questionnaire, Asthma Evaluation Questionnaire, and Asthma Symptom Utility Index during the run-in period.
Statistical analysis
Descriptive statistics were determined, including means (SDs) or medians (25th and 75th percentiles) to describe continuous variables dependent on variable distribution. Counts (percentages) were used to describe categorical variables with nonmissing values. BMI was treated as both a continuous and categorical variable with 3 categories: lean (BMI, < _24.9 kg/m 2 ), overweight (BMI, 25-29.9 kg/m 2 ), and obese (BMI, > _30 kg/m 2 ). The Kolmogorov-Smirnov test was used to determine whether continuous variables were normally distributed. The Kruskal-Wallis or F-test was used to make comparisons across BMI categories as appropriate, followed by pairwise comparisons between weight categories, whereas the x 2 test was used to compare categorical variables. The prevalence of eosinophilic inflammation was defined as the presence of an increased FENO value at 2 thresholds (>50 and >25 ppb), a sputum eosinophil count of greater than 2%, or a blood eosinophil count of greater than 300 cells/mL. 14, 30, 39 Subjects were assigned to noneosinophilic status as long as all 3 factors were nonmissing and lower than the set threshold. Pearson correlation coefficients with 95% CIs (based on Fisher z transformation) were used to determine the relationship among FENO values, IgE levels, sputum eosinophil counts, and blood eosinophil counts overall and within each weight category. Logistic regression analysis was then used to determine whether FENO values, IgE levels, and blood eosinophil counts were predictive of high sputum eosinophil counts (>2%) overall and within each weight category. Regression splines were used to determine whether the relationship between each biomarker and high sputum level was linear, revealing that the natural log transformation provided an approximate linear relationship. Each regression model was adjusted for study (BASALT and TALC), sex, age, BMI, and race (white or nonwhite). A logistic regression model was then used to determine the value (cut point) that best predicted high sputum eosinophil counts for each biomarker. Values were determined by maximizing the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Regression models were applied across all patients and by weight group.
We did not adjust for multiple comparisons because all analyses were exploratory; thus a P value of less than .05 was considered statistically significant. All data analyses were conducted with SAS software (version 9.4; SAS Institute, Cary, NC).
RESULTS
Demographics and baseline characteristics
Six hundred fifty-two subjects were included in the analyses. Significantly more female subjects were found in the obese (70.1%) and lean (72.0%) asthma groups compared with the overweight group (59.5%; P 5 .014, Table I ). The median age for patients who were obese (40 years) or overweight (36 years) was higher compared with that of lean subjects (30 years, P < .001). Furthermore, a larger proportion of obese patients (55.6%) were given a diagnosis of asthma at greater than 12 years of age (P 5 .002) compared with lean (39.3%) or overweight (50.5%) subjects. Lean (69.7%) and overweight (67.2%) asthmatic subjects were more likely to be white compared with obese subjects (47.7%, P <.001). Smoking history, presence of atopy determined by means of skin prick testing, and use of ICSs at baseline did not differ significantly across BMI groups.
Lean (20.1 ppb) and overweight (22.9 ppb) subjects had significantly higher median FENO values in comparison with obese (16.5 ppb) asthmatic subjects (P < .001). FENO values did not differ significantly between lean and overweight subjects (P 5 .068). Lean (145 IU/mL) and overweight (125 IU/mL) subjects also had significantly higher median IgE levels compared with obese (96 IU/mL) subjects (P 5.042), whereas IgE levels did not differ significantly between lean and overweight subjects (P 5 .611). In addition, blood (P 5 .796) and sputum (P 5 .358) eosinophil counts did not differ significantly across BMI groups (Table II) .
Baseline lung function measurements were found to be significantly lower in obese asthmatic subjects compared with lean and overweight asthmatic subjects, including prebronchodilator forced vital capacity, prebronchodilator FEV 1 (absolute and percent predicted), postalbuterol FEV 1 (absolute and percent predicted), and postipratropium FEV 1 (absolute and percent predicted, all P < .001; Table III ). We also determined the prevalence of reversible airway obstruction and hyperresponsiveness as a function of BMI. Across all subjects, we found a low prevalence of reversible airflow obstruction to both albuterol and ipratropium, with only approximately 35% of patients demonstrating reversibility. The remaining 65% of subjects were enrolled in the studies on the basis of a positive methacholine challenge test result with a PC 20 of less than 16 mg/mL in the absence of reversibility. The BMI group had no effect on the prevalence (P 5 .750) or response to methacholine PC 20 (P 5 .967) or on reversibility to ipratropium (P 5 .098); however, reversibility to albuterol (P 5.038) was more prevalent within the overweight (40.5%) and obese (42.8%) groups compared with the lean group (30.7%).
Obese asthmatic subjects had a higher symptom burden, as indicated by higher asthma symptom scores, including higher Asthma Evaluation Questionnaire (P 5 .010), Asthma Control Questionnaire (P < .001), and Asthma Symptom Utility Index (P 5 .005) scores, compared with lean and overweight subjects. In addition, obese subjects had a significant concomitant decrease in Asthma Quality of Life Questionnaire scores (P < .001). Although these symptom burden results are statistically significant, the differences were small and therefore might not be clinically meaningful (Table IV) .
The prevalence of eosinophilic inflammation according to FENO threshold (>25 or >50 ppb), sputum eosinophil count of greater than 2%, or blood eosinophil count of greater than 300 cells/mL was significantly lower in obese compared with lean and overweight asthmatic subjects (P 5 .010) if the FENO threshold was greater than 25 ppb. If the FENO threshold was increased to greater than 50 ppb, then the eosinophilic inflammation was not significantly different (P 5 .311) across BMI categories (Table V) . 
Correlation between FENO values, IgE levels, and blood and sputum eosinophil counts overall and within BMI groups
Overall, statistically significant but relatively weak correlations were observed among all 4 markers of inflammation, ranging from an r value of 0.17 (IgE levels and FENO values) to an r value of 0.22 (sputum and both blood eosinophil counts and FENO values), as demonstrated in Table VI . Pearson correlations were then determined within each weight category. Lean asthmatic subjects were noted to have the strongest correlations between markers of inflammation, with significant correlations found between all biomarkers except sputum eosinophil counts and IgE levels. The strongest correlation within the lean group occurred between sputum eosinophil counts and FENO values (r 5 0.43, P < .001). As BMI increased, the number of significant associations between biomarkers diminished. As such, overweight subjects only demonstrated significant but relatively weak correlations between sputum eosinophil counts and IgE levels (r 5 0.41, P < .001) and blood eosinophil counts and both sputum eosinophil counts (r 5 0.33, P < .001) and FENO values (r 5 0.016, P 5 .039). Within obese subjects, the only significant correlation found was between IgE levels and blood eosinophil counts (r 5 0.33, P < .001); furthermore, all other correlations between inflammatory markers were approximately 0, including correlations with sputum eosinophil counts.
Predicting high sputum eosinophil counts (>2%) overall and within BMI groups
Logistic regression models for FENO values, quantitative IgE levels, and blood eosinophil counts adjusted for study, age, sex, race, and BMI were used to predict high sputum eosinophil counts (>2%) across all subjects and within each weight category (Table  VII) predicted high sputum eosinophil counts. When each weight category was modeled separately, IgE levels were poorly predictive of high sputum eosinophil counts regardless of weight, whereas FENO values were predictive of high sputum eosinophil counts but only in lean asthmatic subjects (OR, 3.89; 95% CI, 1.56-9.65). Lastly, blood eosinophil counts were most predictive of high sputum eosinophil counts in lean [OR, 1.67; 95% CI, 0.98-2.85) and overweight (OR, 3.01; 95% CI, 1.35-6.73) asthmatic subjects but not obese subjects (OR, 0.96; 95% CI, 0.67-1.38). In fact, none of the biomarkers of inflammation significantly predicted the presence of high sputum eosinophil counts in obese asthmatic subjects.
We then used a multivariable logistic regression model to determine the predictive value of using all 3 inflammatory biomarkers in the model while still adjusting for the same baseline descriptors as above. FENO values continued to be predictive of sputum eosinophilia but only in lean subjects (OR, 6.02; 95% CI, 1.86-19.51; P 5 .003). Blood eosinophil counts were no longer predictive in lean subjects when all 3 biomarkers were considered. In overweight subjects blood eosinophil count was most predictive of sputum eosinophilia (OR, 3.33; 95% CI, 1.36-7.78; P 5 .008), indicating that blood eosinophil counts continue to be predictive of sputum eosinophil counts after accounting for the other markers. The combination of all 3 biomarkers did not result in any improvements in the ability to predict high sputum eosinophil counts in obese subjects (Fig 1) .
Cut points for predicting high sputum eosinophil counts (>2%) overall and by weight group
We performed analyses to determine whether cut points existed for each biomarker individually (FENO values, IgE levels, and blood eosinophil counts) for predicting high sputum eosinophil counts across all subjects and by weight group (Table VIII) . The cut points for IgE levels, FENO values, and blood eosinophil counts that maximize sensitivity and specificity differ by weight Data are presented as numbers (percentages). Eosinophilic is defined as a FENO value greater than 25 ppb or greater than 50 ppb (2 thresholds), a sputum eosinophil count of greater than 2%, or a blood eosinophil count of greater than 300 cells/mL. The absence of all 3 denotes noneosinophilic status. *Denotes a statistically significant difference across BMI categories.
category. Obese asthmatic subjects have lower cut points for IgE levels (268 IU), FENO values (14.5 ppb), and blood eosinophil counts (96 cells/mL) than all other groups.
DISCUSSION
The principal finding of this study was that conventional markers of eosinophilic inflammation were poorly predictive of sputum eosinophilia in obese asthmatic subjects. Consistent with other studies, we found that obesity is associated with a more significant respiratory symptom burden and poorer quality-of-life scores concomitant with lower lung function, even in this population of subjects with mild-to-moderate asthma. Furthermore, we demonstrated that obese asthmatic subjects are more likely to be female and older and to have adult-onset asthma.
Our data revealed no differences in baseline sputum and blood eosinophil counts on the basis of obesity. However, there were significant differences in IgE levels and FENO values. Similar to the currently published literature, obesity appeared to result in lower FENO values, but contrary to our expectations based on the available literature, IgE levels were lower in obese than lean asthmatic subjects. 27, 34 Obese asthmatic subjects had a significantly lower prevalence of eosinophilic inflammation defined as sputum eosinophil counts of greater than 2%, blood eosinophil counts of greater than 300 cells/mL, or FENO values of greater than 25 ppb (P 5 .01). However, when a higher FENO threshold is used (>50 ppb), there are no significant differences in the prevalence of eosinophilia (Table V) . There were no significant differences in the prevalence of eosinophilic inflammation on the basis of obesity, and additionally, greater than 85% of subjects in the study had positive skin prick test responses. Although age of onset has been reported as being a key factor in differentiating the eosinophilic and noneosinophilic obesity phenotypes, our data did not reveal any differences in inflammatory markers on the basis of age of onset in obese subjects. 40 Furthermore, our data revealed increasingly poor correlations between markers of inflammation as subjects become gradually more obese. Although lean asthmatic subjects demonstrated a high degree of correlation between FENO values, blood eosinophil counts, sputum eosinophil counts, and IgE levels, these associations became increasingly poor as BMI increased. As a result, obese patients had a significant correlation between IgE levels and blood eosinophil counts. One can postulate that this was secondary to alterations in surrogate markers that led to increased discordance between the actual inflammatory milieu in lung compartments and the surrogate measurements that we obtained clinically. For instance, nitric oxide levels were reduced in obese subjects, and this might have been related to the presence of underlying oxidative stress and subsequent changes in nitric oxide synthase signaling associated with increased asymmetric dimethyl arginine levels, which could result in a lack of concordance between tissue eosinophilia, inflammation, and FENO values. 26, 41 We postulate that the mechanisms that mediate inflammation in a proportion of obese subjects with eosinophilic asthma is similar to that in subjects with lean asthma. However, obese subjects are at higher risk of inaccurate phenotyping on the basis of surrogate markers of inflammation. These surrogate markers are indirect measures of inflammation that can be influenced by conditions in the lungs of obese subjects, such as the presence of higher levels of oxidative stress 42 and adipokine-mediated alterations of eosinophil chemotaxis and survival. [43] [44] [45] These unique influences of obesity have the potential to influence the accuracy of surrogate markers at detecting compartmental eosinophilia.
Additionally, our study was limited by the reliance on sputum and not tissue eosinophils as the gold standard test for eosinophilic inflammation in the lung. The variability in sputum eosinophilia on repeated measures and the potential discordance with tissue eosinophilia, particularly in obese subjects, has been reported and could be a confounding variable. 21, 24 ,25,46 Therefore we cannot be reassured that sputum eosinophilia reliably reflects lung tissue eosinophils; this remains a subject for future study. Other limitations include retrospective data analysis of a cross-sectional rather than longitudinal data set.
We determined the ability of FENO values, blood eosinophil counts, and IgE levels to predict sputum eosinophil counts (>2%). Sputum eosinophil counts have been shown to predict ICS response, and increases in levels of this marker are associated with increased exacerbations. 20, 23, 47 Given the potential clinical importance of these markers in identifying treatment responders, adjusting therapies, and predicting outcomes, we performed nominal logistic regression modeling to determine the receiver operating characteristics of each biomarker. None of the inflammatory markers (FENO values, blood eosinophil counts, and IgE levels) significantly predicted high sputum eosinophil counts. We noted a decrease in AUC with each of these biomarkers with increasing obesity, with only blood eosinophil counts having an AUC of greater than 0.70 for overweight subjects. From the standpoint of precision medicine, these results suggest that obese subjects could be inaccurately assigned to noneosinophilic phenotypes and possibly be excluded from receiving therapies for their asthma that could facilitate improved outcomes. Indeed, most targeted therapies currently in development rely on surrogate biomarkers to identify potential responders to therapy. 11, 30, 48 In conclusion, asthma is a heterogeneous disease regardless of the presence of obesity. However, obesity has a significant effect on the ability of currently available biomarkers of inflammation to accurately detect the type of underlying inflammation present in the lung. Therefore it is imperative that the potential confounding effect of obesity be taken into consideration when interpreting the results of FENO, IgE, and blood and sputum eosinophil measurements. Moreover, these results underscore the need to identify more sensitive biomarkers in this population, perhaps serum periostin, dipeptidyl peptidase 4, or specific cytokines, that might permit more precise and individualized therapy. [49] [50] [51] Clinical implications: The reliance on inflammatory markers to identify responders to various asthma therapies and thus enable personalized treatment of asthmatic subjects makes accurate characterization of inflammation essential in obese asthmatic subjects. 
